Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 21–22

HOS-114849 · Präparat HOS-094169

21  CYP 3A4 inhibition by tipranavir/r Others Theophylline Based on data from the cocktail Theophylline plasma No interaction study study where caffeine (CYP1A2 concentrations should be performed substrate) AUC was reduced by monitored during the first two 43%, tipranavir with ritonavir is weeks of co-administration with expected to decrease theophylline Aptivus, co-administered with concentrations. low dose ritonavir, and the theophylline dose should be Induction of CYP 1A2 by increased as needed. tipranavir/r Desipramine tipranavir, co-administered with Dosage reduction and No interaction study low dose ritonavir, is expected to concentration monitoring of performed increase desipramine desipramine is recommended. concentrations

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): desipramine (HOS-086249) caffeine (HOS-085902) theophylline (HOS-085910) ritonavir (HOS-084521)